P820033/S019: Plasmaflo OP-05 W(A)
FDA’s recorded scope: a change in the acceptance criterion for the opening torque test performed during in-process inspection of the Plasmaflo OP-05W(A) filter
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 2 FDA records to the applicant name Asahi Kasei Medical Co., Ltd.. 1 entry is a PMA supplement. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Sep 30, 2025 to Apr 9, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code MDP appears in 2 of the 2 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P820033, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 1-105 Kanda Jinbocho, Chiyoda-Ku, Tokyo, 101-8101. Recorded on P820033/S019, decision dated Apr 9, 2026.
Separator For Therapeutic Purposes, Membrane Automated Blood Cell/Plasma.
FDA’s recorded scope: a change in the acceptance criterion for the opening torque test performed during in-process inspection of the Plasmaflo OP-05W(A) filter
FDA’s recorded scope: Your supplement requested approval for a change in the supplier of the lubricant, calcium stearate, added to the polyethylene resin used in the manufacture of the hollow fiber of the device.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.